Disc Medicine IRON Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $188.78M+10.6% | $170.64M+14.4% | $149.21M+20.8% | $123.56M+22.7% | $100.73M+4.2% | ||
| $76.82M+17.5% | $65.38M+20.2% | $54.39M+20.3% | $45.2M+20.6% | $37.47M+13.4% | ||
| $265.6M+12.5% | $236.02M+15.9% | $203.6M+20.6% | $168.76M+22.1% | $138.2M+6.5% | ||
| $265.6M+12.5% | $236.02M+15.9% | $203.6M+20.6% | $168.76M+22.1% | $138.2M+6.5% | ||
| $3.55M-1.5% | $3.61M+9.4% | $3.3M+38.5% | $2.38M+61.9% | $1.47M+157% | ||
| $24.29M+0.4% | $24.2M+5.5% | $22.94M-3.8% | $23.84M+7.5% | $22.18M+7.1% | ||
| $293K-18.8% | $361K-19.6% | $449K-2.6% | $461K-1.7% | $469K+32.1% | ||
| -$241.6M-13.9% | -$212.18M-17.2% | -$181.11M-24.6% | -$145.39M-24.8% | -$116.49M-6.5% | ||
| -$6.62-10.5% | -$5.99-12.0% | -$5.35-19.7% | -$4.47-14.0% | -$3.92+1.8% | ||
| -$6.62-10.5% | -$5.99-12.0% | -$5.35-19.7% | -$4.47-14.0% | -$3.92+1.8% | ||
| 144M+3.7% | 138.8M+5.9% | 131.1M+4.2% | 125.9M+8.0% | 116.5M+7.9% | ||
| 144M+3.7% | 138.8M+5.9% | 131.1M+4.2% | 125.9M+8.0% | 116.5M+7.9% | ||
| -$242.71M-14.8% | -$211.51M-16.8% | -$181.13M-24.9% | -$145.06M-25.1% | -$115.96M-6.3% | ||
| $5.09M+376% | $1.07M— | —— | —— | —— | ||
| $230.85M-51.2% | $473.41M+65.8% | $285.53M+4.1% | $274.37M-38.6% | $446.67M+105% | ||
| —— | —— | —— | —— | -$564.9M-93.2% | ||
| -$201.25M-11.6% | -$180.39M-9.6% | -$164.67M-22.7% | -$134.23M-32.0% | -$101.7M-8.3% | ||
| -$1.08M-260% | $677K— | —— | —— | —— | ||
| -$25K-2,400% | -$1K— | —— | —— | —— | ||
| $72K+53.2% | $47K— | —— | —— | —— | ||
| -$265.25M-12.5% | -$235.74M-15.9% | -$203.4M-20.6% | -$168.64M-22.2% | -$138.05M-6.6% | ||
| -$265.6M-12.5% | -$236.02M-15.9% | -$203.6M-20.6% | -$168.76M-22.1% | -$138.2M-6.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Disc Medicine's income statement data come from?
- Every line is extracted from Disc Medicine's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.